Food & Drug Administration v. Brown & Williamson Tobacco Corp. Case Brief

Food & Drug Administration v. Brown & Williamson Tobacco Corp.

529 U.S. 120 | 120 S. Ct. 1291 | 146 L. Ed. 2d 121 | 2000 U.S. LEXIS 2195

Full access

Unlock the video and quiz

The written brief is free to read below. Subscribe to watch the video explainer and take the quiz.

Takeaway

In short, this case held that the FDA could not regulate tobacco under the pre-2009 FDCA because Congress's statutory scheme reserved that major policy choice to Congress, notwithstanding tobacco's fit with the Act's literal drug-and-device language.

Background

In 1996, the FDA concluded that nicotine is a "drug" under the Federal Food, Drug, and Cosmetic Act (FDCA) because it has pharmacological effects, including addiction, stimulation, sedation, and appetite suppression. The agency further concluded that cigarettes and smokeless tobacco are drug-delivery devices, or "combination products," because they deliver nicotine to users. On that basis, the FDA issued rules aimed primarily at reducing youth tobacco use. The rules restricted sales to minors, required age verification, limited vending-machine and self-service sales, barred free samples, restricted tobacco advertising and brand sponsorships, and required a nicotine-delivery-device label.

Tobacco manufacturers, retailers, and advertisers challenged the rules. The District Court held that the FDCA gave the FDA jurisdiction over tobacco products as customarily marketed and upheld the access and labeling restrictions, but invalidated the advertising and promotion restrictions as beyond the agency's restricted-device authority. The Fourth Circuit reversed on the threshold ground that the FDA lacked statutory authority to regulate tobacco products at all. The Supreme Court granted review and affirmed the Fourth Circuit, so it did not reach the separate statutory and First Amendment challenges to particular regulations.

Issues

Issue #1

Whether the FDCA authorizes the FDA to regulate cigarettes and smokeless tobacco as customarily marketed, without manufacturer claims of therapeutic benefit.

Holding

No. Congress directly spoke to the issue through the FDCA's overall structure and later tobacco-specific legislation, and it precluded FDA jurisdiction over tobacco products as customarily marketed.

Reasoning

The Court applied Chevron's first step but emphasized that statutory meaning must be determined from the FDCA as a coherent whole, not from isolated words. Even assuming that nicotine is a drug and tobacco products are devices because manufacturers intend their physiological effects, that reading could not stand if it conflicted with Congress's clearly expressed design for the statute and for tobacco regulation.

A central feature of the FDCA is that regulated drugs and devices must be safe and effective for their intended uses. The Act's misbranding, classification, and premarket-approval provisions require the FDA to prevent the marketing of products that are dangerous when used as directed or that lack a reasonable assurance of safety and effectiveness.

The FDA's own findings established that tobacco products are extraordinarily dangerous when used for their intended effects. Because tobacco's asserted effects—such as satisfying nicotine addiction, stimulation, sedation, and weight control—do not supply therapeutic benefits that outweigh the products' severe health risks, the FDCA's ordinary safety requirements would require their removal from the market if they fell within FDA jurisdiction.

The FDA argued that tobacco could be considered safe because an immediate ban might create worse public-health consequences, including withdrawal, inadequate treatment capacity, and a black market. The Court rejected that approach because the FDCA asks whether the product itself is safe for its intended use, not whether one regulatory option produces better aggregate public-health results than another. A conclusion that a ban would be harmful did not establish that cigarettes or smokeless tobacco were safe as used.

Congress's tobacco-specific statutes confirmed that Congress did not intend the FDA to have this authority. Since 1965, Congress had regulated tobacco through warnings, advertising restrictions, and measures concerning youth access while preserving tobacco commerce rather than ordering a ban. Those statutes were enacted with full awareness of tobacco's serious health effects and nicotine's pharmacological properties.

Congress legislated against the FDA's long and consistent position that it lacked jurisdiction over tobacco absent therapeutic claims by manufacturers. Congress also repeatedly reserved major tobacco-policy choices to itself and prohibited federal agencies from imposing additional health-related labeling requirements on cigarettes and smokeless tobacco. The Court treated this affirmative legislative scheme, rather than mere congressional inaction, as ratifying the FDA's prior position.

Finally, the Court stressed the economic and political magnitude of the FDA's asserted power, which could ultimately include authority to ban tobacco products nationwide. Congress was unlikely to delegate such consequential authority through the FDCA's general drug-and-device definitions, especially after Congress had created a separate tobacco-specific regulatory framework. Thus Chevron deference was unavailable because Congress had clearly withheld the claimed authority.

Dissents

Justice Breyer

Reasoning

Justice Breyer concluded that the FDCA's text directly covers tobacco. Nicotine is an article intended to affect the body's structure or function through chemical action: it reaches the brain, binds to receptors, alters mood, suppresses appetite, and produces addiction. Cigarettes are consequently devices that deliver that drug. In his view, both the statute's broad language and its public-health purpose strongly supported FDA jurisdiction.

He rejected the manufacturers' claim that "intended" requires an express therapeutic claim. The FDA reasonably reads intent to include objective evidence about how a product is designed, distributed, known, and used. Internal tobacco-industry documents showed that manufacturers understood nicotine's physiological effects and designed cigarettes as optimized nicotine-delivery systems, providing ample evidence of the requisite intent even without express health claims.

Justice Breyer also disputed the majority's premise that FDA jurisdiction would compel a ban. The FDCA gives the agency substantial remedial discretion, including authority to restrict a device's sale, distribution, or use under conditions the agency prescribes. Its provisions for banning, recalling, or otherwise controlling dangerous devices generally use permissive language and should not be read to force the agency to choose a remedy that would create greater health risks.

In his view, the FDA could consider the real-world consequences of a sudden ban when evaluating safety and choosing a remedy. An immediate prohibition could drive addicted consumers to a more dangerous black market or produce other harms, while regulated, incremental restrictions could reduce overall risk. Reading the FDCA to require the more dangerous remedy would contradict its overarching purpose of protecting public health.

Justice Breyer found the later tobacco statutes legally inconclusive. They did not expressly withdraw FDA authority, and their narrow label-warning preemption provisions did not prohibit other FDA regulation; Cipollone had already treated such provisions as limited to their text. The 1997 FDA Modernization Act, moreover, expressly stated that it neither affected nor resolved the FDA's authority over tobacco.

He viewed the FDA's earlier disclaimers of authority as largely reflecting an evidentiary inability to prove manufacturer intent without explicit therapeutic claims. Once new internal industry evidence became available and scientific understanding developed, the agency could reasonably change its interpretation and regulatory priorities. Because the FDCA's broad delegation covered nicotine and cigarettes, Justice Breyer would have upheld the FDA's jurisdiction.